Search
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.
Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnDravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. … [A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal
Synonyms: DL-FenfluramineInternational brands: Ponderax PALasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Alimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors.
TGAAC94
go.drugbank.com/drugs/DB06175InvestigationalThe Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038] … tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexEpcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … [L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies.
Loteprednol etabonate
go.drugbank.com/drugs/DB14596ApprovedLoteprednol Etabonate (LE) is a topical corticoid anti-inflammatory. … Moreover, LE was purposefully engineered to be a 'soft drug', one that is designed to be active locally at the site of administration and then rapidly metabolized to inactive components after eliciting
Tegoprazan
go.drugbank.com/drugs/DB16690Investigational[A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. … [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.